Financhill
Back

Dyne Therapeutics Quote, Financials, Valuation and Earnings

Dyne Therapeutics Price Quote

$41.62
+0.17 (+0.41%)
(Updated: July 18, 2024 at 12:30 PM ET)

Dyne Therapeutics Key Stats

Buy
70
Dyne Therapeutics (DYN) is a Buy

Day range:
$41.38 - $43.73
52-week range:
$6.40 - $44.33
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
7.58%

Volume:
879.6K
Avg. volume:
1.1M
1-year change:
274.1%
Market cap:
$3.6B
Revenue:
$0
EPS:
$-3.97

How Much Does Dyne Therapeutics Make?

Data Unavailable

Is Dyne Therapeutics Growing As A Company?

Data Unavailable

Dyne Therapeutics Stock Price Performance

  • Did Dyne Therapeutics Stock Go Up Last Month?
    Dyne Therapeutics share price went up by 30.39% last month
  • Did DYN's Share Price Rise Over The Last Year?
    DYN share price rose by 274.1% over the past 1 year

What Is Dyne Therapeutics 52-Week High & Low?

Dyne Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Dyne Therapeutics?

  • How Much Debt Does Dyne Therapeutics Have?
    Total long term debt quarterly is $0
  • How Much Cash Does Dyne Therapeutics Have?
    Cash and short term investments quarterly total is $453.5M
  • What Is Dyne Therapeutics’s Book Value Per Share?
    Book value per share is 5.49

Is Dyne Therapeutics Cash Flow Positive?

  • What Is DYN Cash Flow From Operations?
    Cash flow from operations (TTM) is -$219.8M
  • What Is Dyne Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $433.9M
  • What Is Dyne Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$123.6M

Dyne Therapeutics Return On Invested Capital

Data Unavailable

Dyne Therapeutics Earnings Date & Stock Price

Dyne Therapeutics Competitors

  • Who Are Dyne Therapeutics's Competitors?
    Below is a list of companies who compete with Dyne Therapeutics or are related in some way:
    • Catalyst Pharmaceuticals Inc (CPRX)
    • Ligand Pharmaceuticals Inc (LGND)
    • Oragenics Inc (OGEN)
    • PTC Therapeutics Inc (PTCT)
    • Vertex Pharmaceuticals Inc (VRTX)

Dyne Therapeutics Dividend Yield

Data Unavailable

Dyne Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 0.25%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 6
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 46.30
Upside from Last Price: 11.7%

Major Shareholders

  • How many DYN shares are owned by institutional investors?
    112.5M DYN shares are owned by institutional investors
  • How many DYN shares are owned by insiders?
    2M DYN shares are owned by insiders